



THE UNITED STATES PATENT AND TRADEMARK OFFICE

#23
IDS
w/attack
3/7/02

TECH CENTER 1600/2900

FEB 19 2002

RECEIVED

In re application of: Chisari, et al. Art Unit: 1762
Serial No.: 08/854,825 Examiner: Parker, F.
Filing Date: May 12, 1997
For: "Hepatitis C Virus-Derived Peptides Capable of Inducing Cytotoxic T Lymphocyte Responses"
Docket No. 329368-101A

Commissioner for Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56

Applicants herein make available to the Patent and Trademark Office copies of the documents:

listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and

listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:

Serial No. _____, filed _____;

Serial No. _____, filed _____;

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under

Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

Further enclosed is an Opposition (by Innogenetics N.V.) which has been filed with respect to a corresponding patent.

(1) **This Information Disclosure Statement is being filed:**

- within three months of the filing date of the patent application.
- within three months of the date of entry into the national stage as set forth in 37 CFR 1.491 of the international application.
- before** the mailing date of a first Office Action on the merits.
- after** the mailing date of the first Office Action on the merits, but before the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by:
 - the Statement under 37 CFR 1.97(e) (see "Statement" below);
or
 - the Fee of \$180.00 set forth in 37 CFR 1.17(p); or
 - No fee is owed by the applicants.
- after** the mailing date of a Final Office Action under 37 CFR 1.116 or a Notice of Allowance under 37 CFR 1.311, and accordingly is accompanied by the Statement under 37 CFR 1.97(e), a Petition requesting consideration of the Information Disclosure Statement and the Petition Fee of \$130.00 set forth in 37 CFR 1.17(i)(1) (see "Statement," "Petition," and "Fees" below).

(2) **Statement**

- The **undersigned attorney** hereby states that each item information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

(If this box is checked, do not check any further Statement boxes.)

or

The person signing immediately below hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

The person making the statement is:

the inventor(s) who sign(s) below:

Signature of the Inventor(s)

Typed or Printed Name of the Inventor(s)

or

a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:

Signature of the Person(s)

Typed or Printed Name of the Person

Address of Person Signing

or

the undersigned attorney who signs on the basis of the information:

supplied by the inventor(s).

supplied by an individual designated in 37 CFR 1.56(c).

in the attorney's file.

Signature of the attorney

(3) **Petition**

Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. *(This box checked only if a Final Office Action has issued)*

(4) **Fees**

No Fee is owed by the applicants.

The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.

The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.

(5) **Method of Payment of Fees**

Charge Account No. 04-0480 in the amount of \$_____ . (A duplicate of this request is attached).

(6) **Authorization to Charge Additional Fees**

If any additional fees are owed in connection with this communication, please charge Deposit Account No. 04-0480.

(7) **Instructions as to Overpayment**

Please credit Account No. 04-0480 for any overpayment.

Please refund Dechert Price & Rhoads in the amount of
\$_____.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: February 11, 2002



Arthur E. Jackson
Registration No. 34,354

DECHERT
Princeton Pike Corporate Center
PO Box 5218
Princeton, New Jersey 08543-5218
127430.1.07